Split Ozurdex implant: A caution

Canadian Journal of Ophthalmology

Volumn 48, Issue 1, 2013, Pages

  Roy, Rupak ^a   Hegde, Sandhya ^a  

^a SANKARA NETHRALAYA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE;

ADULT; CASE REPORT; DIABETIC MACULAR EDEMA; DRUG IMPLANT; DRUG RELEASE; HUMAN; LETTER; MALE; OFF LABEL DRUG USE; OPHTHALMOSCOPY;

EID: 84884211404     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.03.033     Document Type: Letter

References (5)

1. Haller JA, Bandello F, Belfort R Jr, et al. Ozurdex Geneva Study Group. Randomized, sham-controlled trial of dexamethasone intra- vitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-46.
2. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-96.
3. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-17.
4. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. IOVS. 2005;46:1440-4.
5. Chang-Lin J, Burke JA, Peng Q, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. IOVS. 2011;52:80-6.